𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam Preclinical-Clinical Program

✍ Scribed by Eric R. Manusama; Peet T.G. A. Nooijen; Timo L.M. Ten Hagen; Alex H. Van Der Veen; Mark W. R. De Vries; Johannes H. W. De Wilt; Marc G. Van Ijken; Richard L. Marquet; Alexander M. M. Eggermont

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
46 KB
Volume
14
Category
Article
ISSN
8756-0437

No coin nor oath required. For personal study only.

✦ Synopsis

The clinical success of the application of tumor necrosis factor-α (TNFα) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclinical-clinical TNFα program that explores new methods to use TNFα in various settings. Regional organ perfusion models were developed and the effectivity of targeting of TNFα to the tumor by means of systemic administration of liposomes are tested. Furthermore various drugs and mechanisms that may enhance the activity of TNFα are under investigation. A summary of this comprehensive program is presented here. Semin.

📜 SIMILAR VOLUMES

A Phase I trial of continuous hypertherm
A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis
✍ David L. Bartlett; Joseph F. Buell; Steven K. Libutti; Eddie Reed; Kang Bo Lee; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 1 views

## BACKGROUND. Tumor necrosis factor (TNF), hyperthermia, and cisplatin have synergistic cytotoxicity against cancer cells in vitro. This combination may be well suited to the regional treatment of peritoneal tumor spread in patients. Continuous hyperthermic peritoneal perfusion (CHPP) is a techni

B cell depletion may be more effective t
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt